Primary cutaneous large b-cell lymphoma shows activation of nuclear factor kappa B and low incidence of epstein-barr virus

American Journal of Dermatopathology

Volumn 32, Issue 5, 2010, Pages 439-441

  Bhagavathi, Sharathkumar ^a   Blenc, A M ^b   Amin, M ^a   Nikitin, V D ^b   Patel, M C ^b   Warren, S ^a   Malhotra, R K ^b  

^a Laboratory Medicine   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Epstein Barr virus; NF kB; P65; primary cutaneous large B cell lymphoma

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 2; PROTEIN BCL 6; RNA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; AGED; BIOPSY; ENZYME IMMUNOASSAY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENETICS; INCIDENCE; ISOLATION AND PURIFICATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METABOLISM; PATHOLOGY; PROGNOSIS; SKIN NEOPLASMS; VIROLOGY; VIRUS ACTIVATION;

AGED; BIOPSY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; INCIDENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PROGNOSIS; RNA, VIRAL; SKIN NEOPLASMS; TRANSCRIPTION FACTOR RELA; VIRUS ACTIVATION;

EID: 77954115004     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181c1195b     Document Type: Article

References (14)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
2. Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92: 1240-1251.
3. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphoma: a proposal from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
4. Pink-Fuches R, Zenahlik P, Back B, et al. Primary cutaneous lymphomas: applicability of current classification schemes (EORTC, WHO) based on clinicopathologic features observed in a large group of patients. Blood. 2002;99:800-805.
5. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol. 2001;19:3602-3610.
6. Jost PJ, Ruland J. Aberrant NF-B signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007; 109:2700-2707.
7. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671-3678.
8. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappa b activity is required for survival of activated B celllike diffuse large B cell lymphoma cells. J Exp Med. 2001;194: 1861-1874.
9. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: IARC; 2008.
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphomas identified by gene expression profiling. Nature. 2000; 403:503-511.
11. Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106:2491-2497.
12. Gaitonde S, Kavuri S, Alagiozian-Angelova V, et al. EBV positivity in primary cutaneous large B-cell lymphoma with immunophenotypic features of leg type: an isolated incidence or something more significant?. Acta Oncol. 2007;47:461-464.
13. Tokoda Y, Fukushima M, Nakazawa K, et al. A case of primary Epstein Barr virus associated cutaneous diffuse large B-cell lymphoma un-associated with iatrogenic or endogenous immune dysregulation. J Cutan Pathol. 2008;35:666-671.
14. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110: 972-978.